Patents by Inventor Steven A. Kwilas

Steven A. Kwilas has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Respiratory syncytial virus having cleavage-resistant G protein and related materials and methods
    Patent number: 10758607
    Abstract: Embodiments disclosed herein provide compositions, methods, and uses for respiratory syncytial viruses (RSV) and immunogenic compositions thereof. Certain embodiments provide RSV having cleavage-resistant mutated attachment (G) glycoproteins. In some embodiments, the cleavage-resistant G protein mutants increase production of live attenuated RSV in host cells. Also provided are methods for amplifying RSV in host cells, wherein the amplified RSV has full length G protein. In certain embodiments, the amplified RSV having full length G protein is formulated into immunogenic compositions, including vaccines. Other embodiments provide methods for inducing an effective immune response against RSV infection in a subject.
    Type: Grant
    Filed: June 17, 2016
    Date of Patent: September 1, 2020
    Assignee: The Research Institute at Nationwide Children's Hospital
    Inventors: Mark Edward Peeples, Steven A. Kwilas, Jacqueline Dianne Corry
  • RESPIRATORY SYNCYTIAL VIRUS HAVING CLEAVAGE-RESISTANT G PROTEIN AND RELATED MATERIALS AND METHODS
    Publication number: 20190083600
    Abstract: Embodiments disclosed herein provide compositions, methods, and uses for respiratory syncytial viruses (RSV) and immunogenic compositions thereof. Certain embodiments provide RSV having cleavage-resistant mutated attachment (G) glycoproteins. In some embodiments, the cleavage-resistant G protein mutants increase production of live attenuated RSV in host cells. Also provided are methods for amplifying RSV in host cells, wherein the amplified RSV has full length G protein. In certain embodiments, the amplified RSV having full length G protein is formulated into immunogenic compositions, including vaccines. Other embodiments provide methods for inducing an effective immune response against RSV infection in a subject.
    Type: Application
    Filed: June 17, 2016
    Publication date: March 21, 2019
    Inventors: Mark Edward Peeples, Steven A. Kwilas, Jacqueline Dianne Corry